In agreement, small molecule-inhibiting FAK-p53 interactions screened on colon cancer cells reduced cell viability, reactivating p53-dependent transcriptional activity and was synergic with conventional anti-cancer chemotherapeutics [23]. The gene discussed is TP53; the disease is cancer.